Overview of the global solid tumors drugs market

According to the solid tumors drugs industry analysis, this market is projected to witness staggering growth and will post an impressive CAGR of more than 8% over the forecast period. The growing incidence of solid tumors worldwide has resulted in pharmaceutical companies investing heavily in R&D to provide more efficacious and better-tolerated medications. The clinical pipeline for solid tumors is vast, featuring drugs in different stages of development. Moreover, many companies are set to launch 2 to 3 new drugs, which are now in the pipeline, during the forecast period. Around 30% of all biologics awaiting the US FDA’s approval are monoclonal antibodies for the treatment of solid tumors. Some of these drugs include Elotuzumab, Avelumab, and biosimilars of Avastin, MabThera, and Herceptin. Besides these, some molecules are in Phase I/II, pre-clinical, and discovery stages, which will form a robust pipeline for solid tumors in the coming years.

The emergence of biosimilars is one of the emerging solid tumors drugs market trends spurring the growth prospects for this market during the forecast period. Biosimilars, unlike generic drugs, are almost similar to the originator biologic compounds. When developed by different manufacturers, these drugs can differ from the original product, as well as from each other. Also, they cost less than biologics and are therefore more accessible to patients. Some of the major biologics available for the treatment of solid tumors include MabThera, Avastin, Herceptin, Erbitux, and Vectibix. However, patent expiries of the major biologics will result in the emergence of the biosimilars of these drugs. The sales of these biologics may decline during the forecast period due to growth in the sales of their biosimilar versions.

Segmentation by molecule type and analysis of the solid tumors drugs market

• Small molecules
• Biologics

During 2015, the biologics segment dominated the market and accounted for close to 59% of the market share in terms of revenue. This segment consists of medicinal products extracted from biological sources such as human, animal, microorganisms, or they are manufactured using the latest, cutting-edge biotechnological processes. Biologics include products such as enzymes, blood and blood components, gene therapy, recombinant proteins, somatic cells, tissues, and vaccines.

Geographical segmentation and analysis of the solid tumors drugs market

• Americas
• APAC
• EMEA

Based on the solid tumors drugs industry outlook, the Americas dominated the global solid tumors drugs market and is expected to reach more than USD 43 billion by 2020. The growth of this market in the Americas is attributed to the increasing uptake of existing biologics drugs and the launch of new biologics. However, the revenue from these drugs will decrease during the forecast period because of the loss of patent exclusivity of drugs, leading to the entry of generics. This decline is expected to be partially offset by favorable reimbursement plans by the government, such as the provision of Medicare and Medicaid. The US is the largest revenue contributor in this region. The market in the US will grow during the forecast period because of the introduction of novel drugs, which will lead to the vendors earning substantial revenue.

Competitive landscape and key vendors

The competition in the global solid tumors drugs market is intense due to the presence of numerous small and large vendors that operate on a local and global scale. New players are also looking to explore the market because of the growth opportunities. The companies that manufacture and market safe and effective solid tumors drugs are expected to gain a competitive edge over its peers.

Key vendors in this market are 

• Hoffmann-La Roche
• Novartis
• Celgene
• Johnson & Johnson
• Pfizer
• BMS

Other prominent vendors in the market are AbbVie, AbGenomics, ADC Therapeutics, Advantagene, Agensys, Almac Group, Ambrx, Argos Therapeutics, Array BioPharma, Astellas Pharma, AstraZeneca, Bayer, Biogen, Biotech Pharmaceutical, BMS, Boehringer-Ingelheim, Boston Biomedical, Celldex Therapeutics, Chugai Pharmaceutical, Cold Genesys, CTI BioPharma, Daiichi Sankyo, DNAtrix, Ds-Pharma, Eleison Pharmaceuticals, Eli Lilly, Endo Pharmaceuticals, Formation Biologics, Fortress Biotech, Genmab, GSK, Immatics Biotechnologies, Immunogen, Immunomedics, Intas Pharmaceuticals, Kairos Therapeutics, Kyowa Hakko Kirin, MedImmune, Merck, Mersana Therapeutics, Morphotek, Neovii Biotech, NewLink Genetics, Northwest Biotherapeutics, Novartis, OncoMed Pharmaceuticals, Oxford BioTherapeutics, Peregrine Pharmaceuticals, Polaris Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals, Stemcentrx, Synthon Biopharmaceuticals, TG Therapeutics, XBiotech, and Zymeworks.

Key questions answered in the report include

• What will the market size and the growth rate be in 2020?
• What are the key factors driving the global solid tumors drugs market?
• What are the key market trends impacting the growth of the global solid tumors drugs market?
• What are the challenges to market growth?
• Who are the key vendors in the global solid tumors drugs market?
• What are the market opportunities and threats faced by the vendors in the global solid tumors drugs market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global solid tumors drugs market?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

• Solid Tumor Testing Market in the US 2016-2020
• Global Cancer Diagnostic Devices Market 2016-2020
• Global Cancer Immunotherapies Market 2016-2020
• Global Gastric Cancer Drugs Market 2016-2020